(Reuters) -Some countries are restricting use of the AstraZeneca COVID-19 vaccine to certain age groups or suspending use after European and British regulators confirmed possible links to rare blood clots.
Denmark became the first country to stop using the vaccine altogether, as it said results of investigations showed “real and serious side-effects”.
Johnson & Johnson’s single-shot vaccine has also been hit by concerns over blood clots, with European regulators reviewing such cases and U.S. federal health agencies recommending pausing its use for a few days. J&J noted no clear causal relationship had been established between the clots and its vaccine.
The developments pose a risk to vaccination plans in Europe.
Regulators have said the benefits of the AstraZeneca shot outweigh risks.
Anglo-Swedish drugmaker AstraZeneca said it was working with regulators to list the possible brain blood clots as “an extremely rare potential side effect” on the vaccines labels.
As of April 4, the European Medicines Agency had received reports of 169 cases of a rare brain blood clot known as cerebral venous sinus thrombosis (CVST), after 34 million doses had been administered in the European Economic Area. Most cases were in women under 60 years of age.
ASTRAZENECA VACCINE BEING USED, WITH OR WITHOUT RESTRICTIONS
Said on April 8 it recommends people under 50 should get Pfizer’s COVID-19 vaccine in preference to AstraZeneca’s shot.
Has resumed use.
Authorities said they would not limit use of the AstraZeneca vaccine, saying benefits outweigh risks.
The Joint Committee on Vaccination and Immunisation has said an alternative to the vaccine should be given for people under 30 where possible, but people should continue to have a second shot if they have received a first dose.
Resumed inoculations from March 19.
Resumed inoculations on March 19.
Authorities said in early April they would pause offering the vaccine to people under 55 and require a new analysis of the shot’s benefits and risks based on age and gender. On April 13, the country said it had recorded its first case of blood clotting with low platelets.
Suspended use of the vaccine for people under 60 on April 7.
Approved resumption of the vaccine on March 19 but said it should be given only to people aged 55 and over. On April 9, recommended that recipients of a first dose of the AstraZeneca shot who are under 55 should receive a second dose with a messenger RNA vaccine.
Resumed using the AstraZeneca vaccine from March 29, but only for people aged 65 and over.
Has limited use of the vaccine following the death of a nurse from anaphylactic shock, and vaccinations will continue only in full-fledged medical centres, Russian news agency TASS reported on March 19.
Sticking to its guidance from March 31 to limit use of the vaccine to those aged over 60. On April 1, Germany’s vaccine commission recommended people under 60 who have had a first shot of the vaccine should receive a different product for their second dose.
Continuing the vaccine’s rollout.
Resumed use on March 25 after suspending it on March 11.
Resumed using the vaccine on March 22 but warned against its use in people with a low blood platelet count.
On April 12, the country said it was restricting use of the vaccine to those over 60.
Has recommended the vaccine be used only for people over 60, the country’s top health adviser said.
Announced it was restarting administering the shots from March 19.
Restarted use on March 19.
Drug regulator Cofepris said on April 7 it did not “at this time” plan to limit the vaccine’s use but was investigating the information raised by Britain.
Limited use of the vaccine to people over 60, the Dutch government said on April 8.
Health minister said on March 31 the vaccine would be limited to people aged over 60 as a precautionary measure.
Suspended use of the vaccine for people under 60 on April 8.
Has resumed use of the vaccine after temporarily stopping vaccinating people with one batch of the vaccine on March 11.
Resumed use of the shot for people aged 30 or older on April 12. On April 7, it had suspended providing the AstraZeneca shot to people under 60.
From April 8, it was giving the vaccine only to people over 60.
Resumed use of the vaccine on March 25 for people aged 65 and older.
Began use on March 15 after delaying rollout the week before.
COUNTRIES WHERE ASTRAZENECA VACCINE USE SUSPENDED
Suspended administration of the vaccine it was scheduled to receive on March 20 as part of the global vaccines sharing scheme COVAX, the health ministry said.
In a world first, Denmark decided to stop using the AstraZeneca vaccine altogether after initially suspending use of the shot.
Authorities said on March 26 Norway would delay a decision on use of the vaccine, with a decision expected by April 15.
J&J VACCINE DELAYS AND RESTRICTIONS
On April 13, U.S. federal health agencies recommended pausing use of J&J’s COVID-19 vaccine for at least a few days after six women under the age of 50 developed rare blood clots after receiving the shot.
The company said it would delay the rollout of the vaccine to Europe, after regulators said they were reviewing rare blood clots.
Widespread use in the EU had not yet started after the company began delivering the doses in the week beginning April 12. The European drug regulator recommended storing doses already received until its safety committee issues an expedited recommendation
Suspended use of J&J’s vaccine on April 13.
(Reporting by Pushkala Aripaka, Yadarisa Shabong, Manas Mishra, Vishwadha Chander, Amruta Khandekar and Mrinalika Roy in Bengaluru; editing by Josephine Mason, Alison Williams, Timothy Heritage, Larry King, Barbara Lewis)
Worldwide coronavirus cases cross 161.42 million, death toll at 3,488,751
More than 161.42 million people have been reported to be infected by the novel coronavirus globally and 3,488,751 have died, according to a Reuters tally.
Infections have been reported in more than 210 countries and territories since the first cases were identified in China in December 2019.
Interactive graphic tracking global spread of coronavirus: open https://tmsnrt.rs/2FThSv7 in an external browser.
Eikon users can click for a case tracker.
The following table lists the top 50 countries by the number of reported cases. A complete list is available with the above links.
COUNTRIES AND TOTAL DEATHS CONFIRMED DEATHS PER
TERRITORIES CASES 10,000
United States 584,768 32,926,288 17.9
India 262,317 24,046,809 1.94
Brazil 430,417 15,433,989 20.55
France 107,423 5,848,154 16.04
Turkey 44,301 5,095,390 5.38
Russia 254,590 4,922,901 17.62
United Kingdom 127,668 4,446,824 19.21
Italy 123,927 4,146,722 20.51
Spain 79,339 3,604,799 16.95
Germany 85,903 3,579,871 10.36
Argentina 69,254 3,242,103 15.56
Colombia 79,760 3,067,879 16.06
Poland 71,311 2,849,014 18.78
Iran 76,433 2,732,152 9.34
Mexico 219,901 2,375,115 17.43
Ukraine 47,620 2,143,448 10.67
Peru 65,316 1,873,316 20.02
Indonesia 47,823 1,734,285 1.79
Czech Republic 29,857 1,651,178 28.09
South Africa 55,012 1,605,252 9.52
Netherlands 17,423 1,589,282 10.11
Canada 24,825 1,312,408 6.7
Chile 27,520 1,266,601 14.69
Iraq 15,910 1,134,859 4.14
Philippines 18,958 1,131,467 1.78
Romania 29,413 1,070,605 15.11
Sweden 14,275 1,037,126 14.03
Belgium 24,645 1,026,473 21.56
Pakistan 19,384 873,220 0.91
Portugal 16,999 841,379 16.53
Israel 6,379 839,076 7.18
Hungary 29,041 796,390 29.71
Bangladesh 12,102 779,535 0.75
Jordan 9,203 722,754 9.24
Serbia 6,646 705,185 9.52
Switzerland 10,179 679,510 11.96
Japan 11,396 673,821 0.9
Austria 10,455 635,780 11.83
United Arab Emirates 1,626 543,610 1.69
Lebanon 7,569 534,968 11.05
Morocco 9,091 514,670 2.52
Malaysia 1,822 462,190 0.58
Nepal 4,669 439,658 1.66
Saudi Arabia 7,134 431,432 2.12
Bulgaria 17,194 413,320 24.48
Ecuador 19,442 405,783 11.38
Slovakia 12,168 387,162 22.34
Greece 11,322 373,881 10.55
Belarus 2,681 373,351 2.83
Panama 6,288 369,455 15.05
Source: Reuters tally based on statements from health ministries and government officials
Generated at 10:00 GMT.
(Editing by David Clarke)
Canada plots course to fully vaccinated return to gatherings in fall
Canada on Friday said there would be a gradual return to a world with indoor sports and family gatherings as more people get vaccinated, but it did not go as far as the United States in telling people they could eventually ditch their masks.
Canada has administered one dose of a COVID-19 vaccine to just over half its adult population, and the country may be over the worst of its current third wave of infections, Chief Public Health Officer Theresa Tam said.
On Thursday, the U.S. Centers for Disease Control and Prevention (CDC) advised that fully vaccinated people do not need to wear masks outdoors and can avoid wearing them indoors in most places, guidance the agency said will allow life to begin to return to normal.
On Friday, Canada‘s public health agency offered guidelines to the 10 provinces, which are responsible for public health restrictions.
The agency says once 75% of Canadians have had a single dose and 20% are fully vaccinated, some restrictions can be relaxed to allow small, outdoor gatherings with family and friends, camping, and picnics.
Once 75% of those eligible are fully vaccinated in the fall, indoor sports and family gatherings can be allowed again.
“I think masks might be the last layer of that multi-layer protection that we’ll advise people to remove,” Tam told reporters, noting that in Canada colder temperatures meant people would start spending more time indoors in the fall.
“We are taking a bit of a different approach to the United States,” she added. While in most of Canada masks are not required outdoors, they are mandatory indoors.
Less than 4% of Canada‘s adult population has been fully vaccinated compared to more than 36% of Americans.
Prime Minister Justin Trudeau, who has promised that everyone who wants to can be fully vaccinated by September, this week spoke of a “one-dose summer” and a “two-dose fall” without explaining what that might look like.
(Reporting by Steve Scherer and David Ljunggren; Editing by Hugh Lawson)
Delayed 2nd Pfizer/BioNTech shot boosts antibodies in elderly; COVID-19 obesity risk higher for men
The following is a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus.
Delaying second Pfizer/BioNTech dose boosts antibodies in elderly
Delaying the second dose of the Pfizer/BioNTech COVID-19 vaccine beyond the originally recommended three-week gap used by the companies in clinical trials appears to induce a stronger antibody response in the elderly, UK researchers found. Shortly after the vaccine became available, UK health officials advised that the second dose should be given 12 weeks after the first to allow more people to get protected by a first dose early on. In a new paper seen by Reuters and expected to appear on medRxiv on Friday ahead of peer review, researchers found that among 175 people ages 80 to 99, those who got their second dose at 12 weeks had antibody responses that were 3.5 times higher than those who got it after three weeks. Antibodies are only one part of the immune system, and vaccines also generate T cells that fight infections. The peak T cell responses were higher in the group with a three-week interval between doses, and the authors cautioned against drawing conclusions on how protected individuals were based on which dosing schedule they received. (https://reut.rs/3wjPK9B)
Impact of obesity on COVID-19 risks may be greater in men
The known increased risk of severe COVID-19 and death linked to obesity may be even more pronounced for men than women, new data suggest. Researchers studied 3,530 hospitalized COVID-19 patients with an average age of 65, including 1,469 who were obese. In men, moderate obesity was associated with a significantly higher risk of developing severe disease, needing mechanical breathing assistance and dying from COVID-19. (The threshold for moderate obesity is a body mass index (BMI) of 35. In an 5-foot, five-inch tall (1.65 m) adult, that would correspond to a weight of 210 pounds (95 kg). In women, however, only a BMI of 40 or higher, indicating severe obesity, was linked with the increased risks. In a report published in European Journal of Clinical Microbiology & Infectious Diseases, the researchers note that while obesity is known to be linked with body-wide inflammation, patients’ levels of inflammatory proteins did not appear to explain the association between obesity and severe illness. For now, they conclude, “particular attention should be paid” to protecting patients with obesity from the coronavirus, “with priority to vaccination access, remote work, telemedicine, and other measures given the higher risk of adverse outcomes once they are diagnosed with COVID-19.” (https://bit.ly/3eO6GiA)
COVID-19 testing rates low among symptomatic Americans
Sick Americans appear to be passing up opportunities to get tested for coronavirus and thus are likely unknowingly spreading the infection throughout their communities, new research shows. Among 37,000 adults across the United States who participated in a smartphone app survey between March and October 2020, nearly 2,700 reported at least one episode of fever and chills. But according to a report published in JAMA Network Open, only a small fraction reported receiving a COVID-19 test result within seven days of the onset of illness. At first, as tests became more accessible, the numbers improved. In early April 2020, less than 10% of survey participants reporting illness with fever received test results within a week. By late July, that proportion had increased to 24.1%. Throughout the summer and fall, as tests became easier to find, the number of sick participants who reported getting tested remained flat. By late October, only 26% reported receiving a test result within a week of febrile illness. “It’s shocking to me that when people have a fever they’re still not getting tested,” said coauthor Dr. Mark Pletcher of the University of California, San Francisco. “Tests are easy to come by. People might have coronavirus, might be spreading it to their friends and neighbors, and they’re not getting tested.” (https://bit.ly/2QUyMzf)
Open in an external browser for a Reuters graphic on vaccines in development.
(Reporting by Nancy Lapid, Alistair Smout and Ronnie Cohen; Editing by Bill Berkrot